X4 Pharmaceuticals, Inc Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2019 to Q3 2025
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
-
Summary
-
X4 Pharmaceuticals, Inc quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2019 to Q3 2025.
- X4 Pharmaceuticals, Inc Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending September 30, 2025 was $891K.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)